AI Generated COVID Drug Enters Trials : Insilico Medicine, an AI-driven biotech company, will soon start Phase I clinical trials for its AI-designed COVID-19 drug. The oral drug could be an alternative to Paxlovid, the only COVID-19 treatment. This idea is a significant advancement for AI and healthcare collaboration. Alex Zhavoronkov, CEO of Insilico Medicine, discussed the transformative impact of generative AI in various domains. He was thrilled that the company’s AI-made second small-molecule drug was ready for human clinical testing. This info could lead to more treatment options than just Paxlovid.
Paxlovid treats COVID-19 symptoms but has side effects like “Paxlovid rebound,” where patients test positive again after recovery. “Paxlovid mouth” leaves a bad taste after taking it. Concerns were raised about the drug’s effectiveness against new drug-resistant virus strains.The new drug from Insilico may help solve these issues. The pill works against drug-resistant COVID-19. It has stable effects that last longer. With ISM3312, the company reduced viruses and inflammation in lung tests.
Also Read : Flesh Eating Bacteria Alert: CDC Issues Urgent National Health Warning
Insilico’s PandaOmics tool found the target protein in the coronavirus for drug development. Chemistry42 generated molecules to attack the target protein. ISM3312 was a good option and received a patent in April 2020.ISM3312 has broad antiviral activity against different strains and variants of the virus, including SARS and MERS. Due to its versatility, the drug could prevent future COVID-19 outbreaks. ISM3312 is useful beyond just success. It’s easy to make with just two steps and common ingredients. This simplifies drug production and accessibility. ISM3312 is being tested on healthy volunteers in Phase I clinical studies to assess its safety and efficacy. The EG.5 COVID variant is also being tested. By 2023, we should know the study results.
Dr. Harvey Castro, an AI healthcare expert, agrees that ISM3312 is crucial in combating COVID-19. AI-made drugs offer new ways to treat diseases, but staying updated on clinical study data and considering patients’ current medications is crucial.ISM3312 brings hope to the sick. Dr. Castro emphasized consulting healthcare providers for personalized advice and staying updated on research and trials. He cautioned that full trials and approvals are necessary to establish the drug’s efficacy and global safety.As AI innovations like ISM3312 transform medical research, the healthcare community remains dedicated to safe and tested innovation.
Our Reader’s Queries
What is the world’s first AI designed drug to enter clinical trials?
Insilico Medicine, a biotech firm based in Hong Kong, has developed the world’s first anti-fibrotic small molecule inhibitor drug using AI technology. This groundbreaking drug is currently being tested on human patients, marking a significant milestone in the field of medicine. With this innovative development, Insilico Medicine is paving the way for more advanced and effective treatments for fibrosis-related diseases.
Does insilico take AI discovered designer drug into trials to treat pulmonary fibrosis?
Insilico Medicine, a biotech company based in Hong Kong and New York, has harnessed the power of AI to create a promising new drug for idiopathic pulmonary fibrosis, a currently incurable lung disease. The drug is currently undergoing mid-stage clinical trials in both the US and China, with initial results anticipated in early 2025.
How can AI be used in clinical trials?
By utilizing AI and RWD, clinical trial decisions regarding the target patient population can be supported. This includes subgroup discovery, refining trial eligibility criteria, and removing patients who are unlikely to benefit from the treatment. As a result, the length of trials can be shortened, ultimately leading to more efficient and effective outcomes.
What is INS018_055?
Insilico’s AI platforms have discovered and designed INS018_055, a promising anti-fibrotic small molecule inhibitor that could be the first of its kind.